Matching-Adjusted Indirect Comparison (MAIC) of Brexucabtagene Autoleucel (Brexu-cel) and Pirtobrutinib in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)

被引：1

作者：

Chen, Jenny M. H. ^{[1
]}

Zhang, Ina ^{[2
]}

Wu, James J. ^{[3
]}

Wade, Sally W. ^{[4
]}

Nunes, Ana ^{[3
]}

Peng, Weimin ^{[3
]}

Snider, Julia T. ^{[3
]}

Maciel, Dylan ^{[1
]}

Chan, Keith ^{[1
]}

Keeping, Sam ^{[1
]}

Shah, Bijal D. ^{[5
]}

机构：

[1] PRECISIONheor, Vancouver, BC, Canada

[2] PRECISIONheor, Oakland, CA USA

[3] Kite, Santa Monica, CA USA

[4] Wade Outcomes Res Consulting, Salt Lake City, UT USA

[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

来源：

关键词：

D O I：

10.1182/blood-2023-177741

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4